Developer docs
API playgroundTry for free, no card

Search company profiles

honessan pharma

Full company profile

uuid004l5bb

Namestring
honessan pharma
Legal namestring
Honessan Pharma Inc. / Pharma Honessan Inc.
Company typeenum
Private
Founded yearstring
-
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersOakville, Canada
HQ citystring
Oakville
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceutical manufacturing, pharmaceutical in-licensing, contract pharmaceutical manufacturing, pharmaceutical distribution services, Saudi pharmaceutical market
Industry3 codes
PRIMARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAIAJAA
Full-Line Pharmaceutical Wholesalers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAGAMAD
Specialty Pharma & Biologics Distribution (GDP-compliant)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Specialty Pharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Specialty Pharmaceutical Products
TypeOne Time License
Description

Sale of specialty care prescription pharmaceutical products across therapeutic areas including Diabetes, Cardiovascular, Gastrointestinal, Nephrology, Immunosuppressants, and Hospital Line. Products are distributed through partners across Saudi Arabia and export markets.

honessanpharma.com
2In-licensing and Distribution
TypeLicensing Royalties
Description

Strategic in-licensing of specialty care products from global pharmaceutical partners for registration and commercialization in Saudi Arabia and GCC markets.

honessanpharma.com
3Contract Manufacturing Services
TypeManaged Services
Description

Manufacturing capacity available for CDMO services, with approximately 350 million standard units annual capacity across multiple dosage forms for regional and global markets.

honessanpharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Infrastructure, Operations, Personnel, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Gitodux
Description

Flagship product - Vonoprazan, the first potassium-competitive acid blocker (PCAB) in Saudi Arabia for acid-related disorders.

honessanpharma.com
Core offering1 text field

Honessan Pharma develops, in-licenses, and distributes a portfolio of 20+ specialty pharmaceutical products across six therapeutic areas (Gastrointestinal, Diabetes, Cardiovascular, Nephrology, Immunosuppressants, Hospital Line), anchored by Gitodux (Vonoprazan), the first potassium-competitive acid blocker (PCAB) registered in Saudi Arabia. The company is building a 32,000 m² GMP-compliant manufacturing facility in Al Madinah Al Munawwarah (commissioning Q4 2027) with ~350 million standard units annual capacity spanning oral solids, semi-solids/topicals, and sterile injectables, and offers CDMO capacity, technology transfer, and licensing partnerships for the Saudi Arabia and GCC markets.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • First PCAB (potassium-competitive acid blocker) approved in Saudi Arabia - Gitodux (Vonoprazan)
+3 more records
Product overview1 text field

Honessan Pharma operates as a specialty pharmaceutical company with a portfolio of 20+ specialty care products spanning six therapeutic areas: Gastrointestinal, Diabetes, Cardiovascular, Nephrology, Immunosuppressants, and Hospital Line. The company's flagship product is Gitodux (Vonoprazan), the first PCAB approved in Saudi Arabia. Honessan Pharma provides end-to-end pharmaceutical solutions encompassing advanced R&D, world-class GMP manufacturing, and strategic product distribution. The manufacturing facility in Al-Madinah Al-Monawara produces oral solids, semi-solids, and injectables with an annual capacity of approximately 350 million standard units.

Product and service4 records
1Gitodux (Vonoprazan)
CategorySpecialty Pharmaceutical — Gastrointestinal
Description

Flagship specialty pharmaceutical product of Honessan Pharma; the first potassium-competitive acid blocker (PCAB) registered in Saudi Arabia, offering next-generation therapy for acid-related disorders with superior and consistent acid suppression compared to traditional PPIs. Targeted at gastroenterology prescribers and patients with acid-related gastrointestinal conditions in Saudi Arabia.

2Sitagliptin (Diabetes Portfolio)
CategorySpecialty Pharmaceutical — Diabetes
Description

Registered specialty pharmaceutical product for diabetes treatment, expanding Honessan Pharma's Diabetes therapeutic area portfolio in Saudi Arabia. Targeted at endocrinologists, diabetologists, and patients requiring diabetes therapy.

3Pharmaceutical Contract Manufacturing (CDMO) Services
CategoryPharmaceutical Manufacturing Services (CDMO)
Description

Planned contract manufacturing / CDMO capacity from Honessan Pharma's 32,000 m² GMP-compliant manufacturing facility in Al Madinah Al Munawwarah, producing oral solid dosage forms (tablets, capsules, film-coated products), semisolid and topical products (creams, ointments, gels), and sterile injectables (vials, ampoules, parenteral preparations). Targeted at global and regional pharmaceutical companies seeking GMP manufacturing capacity in the Middle East.

4Specialty Pharmaceutical In-Licensing & Distribution Partnerships
CategoryPharmaceutical In-Licensing and Distribution
Description

Strategic in-licensing and partnership program through which Honessan Pharma registers, commercializes, and distributes specialty pharmaceutical products from global partners (e.g., Batavia Biosciences, Seacross, Invent Farma, Combino Pharm, aRDi Farma, Razi Al-Madina, Ekuberg Pharma) across Saudi Arabia, GCC, Iraq, and Africa, supported by the Al-Naghi distribution agreement for Saudi Arabia. Targeted at global pharmaceutical companies seeking Middle East/GCC market entry.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-01-01
Description

Distribution agreement signed in 2024 for distribution of pharmaceutical products across Saudi Arabia. Al-Naghi is a trusted healthcare and pharmaceutical distribution partner in Saudi Arabia.

2Batavia Biosciences
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Global pharmaceutical partner specializing in vaccine and biopharmaceutical development. Part of Honessan's network of pharmaceutical partnerships for innovative product development.

honessanpharma.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Contract research organization providing clinical development services. Partner in Honessan's collaborative approach spanning the pharmaceutical value chain.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Pharmaceutical development partner contributing to Honessan's product portfolio and technology capabilities.

5Invent Farma
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Pharmaceutical partner providing specialty products and manufacturing capabilities for the Saudi and GCC markets.

honessanpharma.com
6Combino Pharm
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Pharmaceutical company specializing in sterile and specialty products. Strategic partner in Honessan's product supply network.

honessanpharma.com
7Seacross Pharmaceuticals
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Global pharmaceutical partner contributing specialty products to Honessan's portfolio for Saudi market registration.

honessanpharma.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Pharmaceutical quality and compliance partner in Honessan's network.

9aRDi Farma
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Regional pharmaceutical partner providing specialty products for the Middle East market.

honessanpharma.com
10Razi Al-Madina Pharmaceutical
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Regional pharmaceutical manufacturer and partner in the Saudi pharmaceutical ecosystem.

honessanpharma.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

One of the largest Saudi pharmaceutical manufacturers producing branded generics and specialty products. Directly comparable as a Saudi-based pharma manufacturer with a multi-therapeutic portfolio and Vision 2030 alignment.

TypeDirect peer
Description

MENA-focused specialty and generic pharmaceutical company with branded, injectable, and manufacturing operations. Comparable for specialty pharma positioning across the Middle East and adjacent distribution model.

TypeRegional player
Description

Egypt-based pharmaceutical manufacturer with multi-therapeutic portfolio and regional MENA distribution. Comparable regional specialty pharma manufacturer with similar market positioning across the Middle East.

TypeBroad incumbent
Description

Global generic and specialty pharmaceutical manufacturer with CDMO/CMO services and large-scale API/finished dose capacity. Comparable for the planned CDMO revenue stream and integrated manufacturing platform.

TypeBroad incumbent
Description

Global pharmaceutical manufacturer with strong specialty portfolio across respiratory, cardiovascular, and other chronic segments; comparable for therapeutic area overlap and emerging-market distribution strategy.

TypeBroad incumbent
Description

Global integrated pharmaceutical company with significant CDMO services, specialty portfolio, and emerging market operations. Comparable for planned CDMO services and specialty pharmaceutical business model.

7Saudi Drug Store Company (SDSC)
TypeDirect peer
Description

Leading pharmaceutical distributor in Saudi Arabia. Directly comparable to Honessan's distribution channel function and represents an alternative route to market for KSA-launched specialty pharma products.

TypeEmerging player
Description

Specialty pharma manufacturer with strong presence in emerging markets and manufacturing in multiple regions. Comparable for specialty pharma focus and emerging-market distribution strategy.

9Julphar (Gulf Pharmaceutical Industries)
TypeRegional player
Description

UAE-based pharmaceutical manufacturer with manufacturing across multiple dosage forms and MENA distribution. Regional peer operating similar specialty pharma + manufacturing model but with broader geographic footprint.

TypeDirect peer
Description

Saudi Pharmaceutical Industries & Medical Appliances Corporation — major Saudi pharma manufacturer with branded generics, specialty products, and CDMO capabilities. Closest direct comp for local manufacturing + specialty distribution in KSA.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

honessan pharma

Specialty Pharmaceuticalshonessanpharma.com

honessan pharma firmographics

Firmographics
Name
honessan pharma
Legal name
Honessan Pharma Inc. / Pharma Honessan Inc.
Website
https://honessanpharma.com
Company type
Private
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

honessan pharma industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAIAJAA
Full-Line Pharmaceutical Wholesalers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAGAMAD
Specialty Pharma & Biologics Distribution (GDP-compliant)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences

Keywords

  • Specialty pharmaceutical manufacturing
  • Pharmaceutical in-licensing
  • Contract pharmaceutical manufacturing
  • Pharmaceutical distribution services
  • Saudi pharmaceutical market

Where honessan pharma is headquartered

Location

Headquarters

HQ city
Oakville
HQ country
Canada
HQ region
North America

Offices4 records

Markets served

honessan pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Infrastructure, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

  1. Specialty Pharmaceutical Products: Sale of specialty care prescription pharmaceutical products across therapeutic areas including Diabetes, Cardiovascular, Gastrointestinal, Nephrology, Immunosuppressants, and Hospital Line. Products are distributed through partners across Saudi Arabia and export markets.
  2. In-licensing and Distribution: Strategic in-licensing of specialty care products from global pharmaceutical partners for registration and commercialization in Saudi Arabia and GCC markets.
  3. Contract Manufacturing Services: Manufacturing capacity available for CDMO services, with approximately 350 million standard units annual capacity across multiple dosage forms for regional and global markets.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

honessan pharma product offering

Product offering

Core offering

Honessan Pharma develops, in-licenses, and distributes a portfolio of 20+ specialty pharmaceutical products across six therapeutic areas (Gastrointestinal, Diabetes, Cardiovascular, Nephrology, Immunosuppressants, Hospital Line), anchored by Gitodux (Vonoprazan), the first potassium-competitive acid blocker (PCAB) registered in Saudi Arabia. The company is building a 32,000 m² GMP-compliant manufacturing facility in Al Madinah Al Munawwarah (commissioning Q4 2027) with ~350 million standard units annual capacity spanning oral solids, semi-solids/topicals, and sterile injectables, and offers CDMO capacity, technology transfer, and licensing partnerships for the Saudi Arabia and GCC markets.

Product overview

Honessan Pharma operates as a specialty pharmaceutical company with a portfolio of 20+ specialty care products spanning six therapeutic areas: Gastrointestinal, Diabetes, Cardiovascular, Nephrology, Immunosuppressants, and Hospital Line. The company's flagship product is Gitodux (Vonoprazan), the first PCAB approved in Saudi Arabia. Honessan Pharma provides end-to-end pharmaceutical solutions encompassing advanced R&D, world-class GMP manufacturing, and strategic product distribution. The manufacturing facility in Al-Madinah Al-Monawara produces oral solids, semi-solids, and injectables with an annual capacity of approximately 350 million standard units.

Differentiator

Problem solved

Functional benefit

Brands

  • Gitodux: Flagship product - Vonoprazan, the first potassium-competitive acid blocker (PCAB) in Saudi Arabia for acid-related disorders.

Products and services

  • Gitodux (Vonoprazan) Flagship specialty pharmaceutical product of Honessan Pharma; the first potassium-competitive acid blocker (PCAB) registered in Saudi Arabia, offering next-generation therapy for acid-related disorders with superior and consistent acid suppression compared to traditional PPIs. Targeted at gastroenterology prescribers and patients with acid-related gastrointestinal conditions in Saudi Arabia.
  • Sitagliptin (Diabetes Portfolio) Registered specialty pharmaceutical product for diabetes treatment, expanding Honessan Pharma's Diabetes therapeutic area portfolio in Saudi Arabia. Targeted at endocrinologists, diabetologists, and patients requiring diabetes therapy.
  • Pharmaceutical Contract Manufacturing (CDMO) Services Planned contract manufacturing / CDMO capacity from Honessan Pharma's 32,000 m² GMP-compliant manufacturing facility in Al Madinah Al Munawwarah, producing oral solid dosage forms (tablets, capsules, film-coated products), semisolid and topical products (creams, ointments, gels), and sterile injectables (vials, ampoules, parenteral preparations). Targeted at global and regional pharmaceutical companies seeking GMP manufacturing capacity in the Middle East.
  • Specialty Pharmaceutical In-Licensing & Distribution Partnerships Strategic in-licensing and partnership program through which Honessan Pharma registers, commercializes, and distributes specialty pharmaceutical products from global partners (e.g., Batavia Biosciences, Seacross, Invent Farma, Combino Pharm, aRDi Farma, Razi Al-Madina, Ekuberg Pharma) across Saudi Arabia, GCC, Iraq, and Africa, supported by the Al-Naghi distribution agreement for Saudi Arabia. Targeted at global pharmaceutical companies seeking Middle East/GCC market entry.

Quantifiable outcome

  • First PCAB (potassium-competitive acid blocker) approved in Saudi Arabia - Gitodux (Vonoprazan)
  • +3 more outcomes

Companies that use honessan pharma

Customer profile

Segments3 records

Ideal customer profiles2 records

honessan pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature2 records

honessan pharma partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and minor.

  • Al-NaghicoreChannel Partner/ Reseller/ Distributor · 1 January 2024Distribution agreement signed in 2024 for distribution of pharmaceutical products across Saudi Arabia. Al-Naghi is a trusted healthcare and pharmaceutical distribution partner in Saudi Arabia.
  • Batavia BiosciencesminorStrategic or Co-development PartnerGlobal pharmaceutical partner specializing in vaccine and biopharmaceutical development. Part of Honessan's network of pharmaceutical partnerships for innovative product development.
  • PSI CROminorStrategic or Co-development PartnerContract research organization providing clinical development services. Partner in Honessan's collaborative approach spanning the pharmaceutical value chain.
  • Ekuberg PharmaminorStrategic or Co-development PartnerPharmaceutical development partner contributing to Honessan's product portfolio and technology capabilities.
  • Invent FarmaminorStrategic or Co-development PartnerPharmaceutical partner providing specialty products and manufacturing capabilities for the Saudi and GCC markets.
  • Combino PharmminorStrategic or Co-development PartnerPharmaceutical company specializing in sterile and specialty products. Strategic partner in Honessan's product supply network.
  • Seacross PharmaceuticalsminorStrategic or Co-development PartnerGlobal pharmaceutical partner contributing specialty products to Honessan's portfolio for Saudi market registration.
  • GüteMedminorStrategic or Co-development PartnerPharmaceutical quality and compliance partner in Honessan's network.
  • aRDi FarmaminorStrategic or Co-development PartnerRegional pharmaceutical partner providing specialty products for the Middle East market.
  • Razi Al-Madina PharmaceuticalminorStrategic or Co-development PartnerRegional pharmaceutical manufacturer and partner in the Saudi pharmaceutical ecosystem.

Scale indicators8 records

Recent moves7 records

Expansion highlights4 records

honessan pharma competitors and assessment

Company assessment

Direct peers

  • Tabuk Pharmaceuticals: One of the largest Saudi pharmaceutical manufacturers producing branded generics and specialty products. Directly comparable as a Saudi-based pharma manufacturer with a multi-therapeutic portfolio and Vision 2030 alignment.
  • Hikma Pharmaceuticals: MENA-focused specialty and generic pharmaceutical company with branded, injectable, and manufacturing operations. Comparable for specialty pharma positioning across the Middle East and adjacent distribution model.
  • Saudi Drug Store Company (SDSC): Leading pharmaceutical distributor in Saudi Arabia. Directly comparable to Honessan's distribution channel function and represents an alternative route to market for KSA-launched specialty pharma products.
  • SPIMACO Addwaeih: Saudi Pharmaceutical Industries & Medical Appliances Corporation — major Saudi pharma manufacturer with branded generics, specialty products, and CDMO capabilities. Closest direct comp for local manufacturing + specialty distribution in KSA.

Regional players

  • Pharco Pharmaceuticals: Egypt-based pharmaceutical manufacturer with multi-therapeutic portfolio and regional MENA distribution. Comparable regional specialty pharma manufacturer with similar market positioning across the Middle East.
  • Julphar (Gulf Pharmaceutical Industries): UAE-based pharmaceutical manufacturer with manufacturing across multiple dosage forms and MENA distribution. Regional peer operating similar specialty pharma + manufacturing model but with broader geographic footprint.

Broad incumbents

  • Aurobindo Pharma: Global generic and specialty pharmaceutical manufacturer with CDMO/CMO services and large-scale API/finished dose capacity. Comparable for the planned CDMO revenue stream and integrated manufacturing platform.
  • Cipla: Global pharmaceutical manufacturer with strong specialty portfolio across respiratory, cardiovascular, and other chronic segments; comparable for therapeutic area overlap and emerging-market distribution strategy.
  • Dr. Reddy's Laboratories: Global integrated pharmaceutical company with significant CDMO services, specialty portfolio, and emerging market operations. Comparable for planned CDMO services and specialty pharmaceutical business model.

Emerging players

  • Aspen Pharmacare: Specialty pharma manufacturer with strong presence in emerging markets and manufacturing in multiple regions. Comparable for specialty pharma focus and emerging-market distribution strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

honessan pharma social profiles

Digital presence

honessan pharma compliance and trust

Trust signal

Compliance1 record

honessan pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

honessan pharma leadership team

Management profile

Number of profiles

honessan pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

honessan pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about honessan pharma

What does honessan pharma do?

Honessan Pharma develops, in-licenses, and distributes a portfolio of 20+ specialty pharmaceutical products across six therapeutic areas (Gastrointestinal, Diabetes, Cardiovascular, Nephrology, Immunosuppressants, Hospital Line), anchored by Gitodux (Vonoprazan), the first potassium-competitive acid blocker (PCAB) registered in Saudi Arabia. The company is building a 32,000 m² GMP-compliant manufacturing facility in Al Madinah Al Munawwarah (commissioning Q4 2027) with ~350 million standard units annual capacity spanning oral solids, semi-solids/topicals, and sterile injectables, and offers CDMO capacity, technology transfer, and licensing partnerships for the Saudi Arabia and GCC markets.

Is honessan pharma a public or private company?

honessan pharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was honessan pharma founded?

honessan pharma was founded in -1. It employs 1 to 10 people.

Where is honessan pharma based?

honessan pharma is headquartered in Oakville, Canada, in the North America region.

How does honessan pharma make money?

Three revenue lines are on record. Specialty Pharmaceutical Products are the primary driver. The others are in-licensing and Distribution and contract Manufacturing Services.

Who are honessan pharma's main competitors?

Direct peers on record are Tabuk Pharmaceuticals, Hikma Pharmaceuticals, Saudi Drug Store Company (SDSC) and SPIMACO Addwaeih. Regional players are Pharco Pharmaceuticals and Julphar (Gulf Pharmaceutical Industries). Broad incumbents are Aurobindo Pharma, Cipla and Dr. Reddy's Laboratories. Aspen Pharmacare is listed as an emerging player.

Does honessan pharma have an API?

No public API is recorded for honessan pharma.

What industry is honessan pharma in?

honessan pharma's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIABAI, Contract Development & Manufacturing for Generics (CDMO/CMO), with a secondary code of HLAIAJAA, Full-Line Pharmaceutical Wholesalers. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales